Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine ...

Niagen Bioscience CEO Robert Fried discusses the science of NAD, the problems with the supplement industry, and how his company is leading the way in anti-aging research.

Niagen Bioscience can either commercialise the drug candidate independently or sublicense to a strategic pharmaceutical ...

Executives from Niagen Bioscience, Pushly, and VidaCorp discuss brand evolution. Learn why authenticity, community, and AI are key to building a resilient brand.

Investing.com -- Niagen Bioscience Inc (NASDAQ: NAGE) stock rose 2% after the company announced an exclusive worldwide commercial license agreement with Norway’s Haukeland University Hospital to ...

Niagen Bioscience, Inc., the global authority on NAD+ with a focus on the science of healthy aging, today announces that senior management will participate at the Roth 15 th Annual London ...

Niagen Bioscience Inc. has reached a significant milestone as its stock hit a 52-week high of 14.49 USD, with InvestingPro data showing the company maintains a "GREAT" overall financial health ...

View the latest Niagen Bioscience Inc. (NAGE) stock price, news, historical charts, analyst ratings and financial information from WSJ.

The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full ...

Niagen Bioscience CFO, Ozan Pamir, will attend in-person one-on-one meetings with institutional investors throughout the conference.

Niagen Bioscience Inc. (NASDAQ:NAGE) saw its stock rise 2% after securing an exclusive global commercial license from Norway’s Haukeland University Hospital to develop its nicotinamide riboside ...